Treatment of serious bleeds with an antihaemophilic factor VIII (recombinant), porcine sequence (OBI-1) in patients with acquired haemophilia A

被引：0

作者：

Kruse-Jarres, R. ^{[1
]}

St-Louis, J. ^{[2
]}

Greist, A. ^{[3
]}

Shapiro, A. ^{[3
]}

Smith, H. ^{[4
]}

Chowdary, P. ^{[5
,6
]}

Drebes, A. ^{[5
,6
]}

Gomperts, E. ^{[7
]}

Bourgeois, C. ^{[8
]}

Mo, M. ^{[9
]}

Novack, A. ^{[9
]}

Farin, H. ^{[9
]}

Ewenstein, B. ^{[9
]}

机构：

[1] Tulane Univ, Sect Hematol Oncol, New Orleans, LA 70118 USA

[2] Univ Montreal, Div Hematol, Hop Maison Neuve Rosemont, Montreal, PQ, Canada

[3] Haemophilia & Thrombosis Ctr, Indianapolis, IN USA

[4] Tufts Univ New England Med Ctr, Div Hematol Oncol, Boson, MA USA

[5] Royal Free Hosp, Katharine Dormandy Haemophilia Ctr, London NW3 2QG, England

[6] Royal Free Hosp, Thrombosis Unit, London NW3 2QG, England

[7] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA

[8] Baxter BioSci, Vienna, Austria

[9] Baxter Healthcare, Westlake Village, CA USA

来源：

HAEMOPHILIA | 2015年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PP081

引用

页码：62 / 62

页数：1

共 50 条

[31] Acquired hemophilia a hemostatic treatment with recombinant porcine factor VIII
Sobolewska, A.
Urbanska, A.
Bednarska, M.
Zawadzka, I.
Witkowski, M.
CLINICA CHIMICA ACTA, 2024, 558
[32] The First Italian Experience of Clinical Use of Obizur, Recombinant Porcine Sequence Factor Viii (rPFVIII), for Acquired Haemophilia A (AHA)
Lodigiani, C.
Ferrazzi, P.
Libre, L.
Pacetti, V.
Colombo, A.
Francescut, C.
Beltrametti, M. C.
Quaglia, I.
HAEMOPHILIA, 2017, 23 : 52 - 53
[33] Factor VIII:C measurement by different chromogenic and one stage assays in two Acquired Haemophilia patients treated with recombinant porcine factor VIII
Guy, Susan
Bowyer, Annette
Kitchen, Steve
HAEMOPHILIA, 2022, 28 : 47 - 48
[34] Effect of OBI-1, a recombinant FVIII product with porcine FVIII sequence, on thrombin generation and clot structure in plasma from hemophilia A patients with inhibitors
Negrier, Claude
Oldenburg, Johannes
Poetzsch, Bernd
Bordet, Jean-Claude
Al Dieri, Raed
Dargaud, Yesim
Hemker, Coen
Lee, Martin
Turecek, Peter L.
HAEMOPHILIA, 2014, 20 : 3 - 3
[35] Short-term efficacy of recombinant porcine factor VIII in patients with acquired factor VIII inhibitors
Abou-Ismail, M.
Vuyyala, S.
Prunty, J.
Schmaier, A.
Nayak, L.
HAEMOPHILIA, 2019, 25 : 3 - 3
[36] Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS
Miesbach, Wolfgang
Curry, Nicola
Knoebl, Paul
Percy, Charles
Santoro, Rita
Schmaier, Alvin H.
Trautmann-Grill, Karolin
Badejo, Kayode
Chen, Jie
Nouri, Masoud
Oberai, Pooja
Klamroth, Robert
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
[37] Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
Pfrepper, Christian
Klamroth, Robert
Ettingshausen, Carmen Escuriola
Petros, Sirak
Siegemund, Annelie
Siegemund, Thomas
HAEMOPHILIA, 2024, 30 (02) : 545 - 553
[38] The in vitro procoagulant effect of recombinant porcine factor VIII in patients with inherited haemophilia A and inhibitors
Dargaud, Yesim
Nougier, Christophe
Desage, Stephanie
Meunier, Sandrine
Lienhart, Anne
HAEMOPHILIA, 2022, 28 : 40 - 41
[39] Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors
Mahlangu, J. N.
Andreeva, T. A.
Macfarlane, D. E.
Walsh, C.
Key, N. S.
HAEMOPHILIA, 2017, 23 (01) : 33 - 41
[40] Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A
Seki, Yoshinobu
Ogawa, Yoshiyuki
Kikuchi, Takahide
Sakaida, Emiko
Mizuta, Yuki
Kitagawa, Tadayuki
Takemura, Kazuhiko
Miyaguchi, Yasuo
Nogami, Keiji
Matsushita, Tadashi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (04) : 482 - 491

← 1 2 3 4 5 →